Results 201 to 210 of about 790,096 (261)

Multiple switches between infliximab originator and biosimilars in pediatric inflammatory bowel disease. [PDF]

J Pediatr Gastroenterol Nutr
De Groote S, van Hoeve K, Dreesen E, Hoffman I.   +3 more
europepmc   +1 more source

Risk management in the distribution process of biosimilar products in the pharmaceutical industry

, 2016
openaire   +1 more source

Patient out-of-pocket costs and rheumatology biosimilar competition. [PDF]

J Manag Care Spec Pharm
Dayer VW, Hansen RN, Roth J, Jofre-Bonet M, Sullivan SD.   +4 more
europepmc   +1 more source

Comparative assessment of asparaginase activity, population pharmacokinetics, and safety of biosimilar native Escherichia coli and pegylated asparaginase in children with newly diagnosed acute lymphoblastic leukemia: a pharmacometrics-based randomized clinical trial. [PDF]

BMC Cancer
Sethuramalingam S, Mohapatra S, Agarwal PK, Kumar-M P, Hota D, Gopal J, Kulkarni A, Srinivasan A.   +7 more
europepmc   +1 more source

Safety and effectiveness of rituximab biosimilar (Rituximab-GP2013) versus originator in rheumatoid arthritis: real-world evidence from a single center. [PDF]

Clinics (Sao Paulo)
Bayeh B, Reyes-Neira F, Bonfiglioli KR, Aikawa NE, Assad APL, Miossi R, de Souza FHC, Insfran CE, Giardini HAM, Yuki EFN, Franco A, Domiciano DS, de Moraes JCB, Bonfa E, Saad CGS, de Medeiros-Ribeiro AC, Shimabuco AY.   +16 more
europepmc   +1 more source

Biosimilars in Adult and Pediatric Noninfectious Uveitis. [PDF]

Clin Ophthalmol
Ploeger CG, Carvalho Soares Valentim C, Guner ME, Kabaalioglu Guner M.   +3 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Gel Electrophoretic Methods for The Analysis of Biosimilar Pharmaceuticals Using The Example of Recombinant Erythropoietin

Bioanalysis, 2013
Due to their versatility and cost-effectiveness, gel electrophoretic methods provide an important set of tools for the analysis of therapeutic proteins. As an increasing number of biosimilar pharmaceuticals are entering the market, techniques are required that allow reliable demonstration of comparability of these products with the reference products ...
Mario Thevis, Christian Reichel
exaly   +4 more sources

Efforts of the Pharmaceuticals and Medical Devices Agency of Japanese regulatory agency in supporting biosimilar development and disseminate information

Naunyn-Schmiedeberg's Archives of Pharmacology
Information on biosimilars was rarely disseminated on the Pharmaceuticals and Medical Devices Agency (PMDA) website of the Japanese Regulatory Agency until the fiscal year (FY) 2022. Therefore, the PMDA website for biosimilars was created in FY 2023.
Ryosuke Kuribayashi
exaly   +4 more sources

Survey on the Role of Comparative Efficacy Studies Required for Biosimilar Monoclonal Antibody Approval in Japan to Justify the Quality Attribute Differences Between Biosimilars and Their Reference Products Based on the Pharmaceuticals and Medical Devices Agency (PMDA) Assessments

Pharmaceutical Medicine
Ryosuke Kuribayashi
exaly   +2 more sources

Can biosimilar products be interchangeable? Pharmaceutical perspective in the implementation of biosimilars in oncology

Journal of Oncology Pharmacy Practice, 2021
Objective To evaluate the safety in the interchangeability of biosimilar products approved for cancer treatment from a pharmaceutical perspective. Methods A literature review was carried out using the descriptors “Biosimilar ...
José Cleberson Santos Soares, Iago Dillion Lima Cavalcanti, Juliana Lúcia de Albuquerque Vasconcelos   +2 more
openaire   +2 more sources